Skip to main content
. 2015 Jun 23;20:58–70. doi: 10.1007/s10157-015-1132-0

Table 2.

Time-averaged values in the time-averaged dataset according to the decline of eGFR

Characteristics p value§ (vs. baseline) Total (n = 770) Group 1 (n = 561) Group 2 (n = 137) Group 3 (n = 72) p value
Observation period (years) 4.1 ± 1.6 4.4 ± 1.5 4.0 ± 1.4*** 2.0 ± 0.7***,† <0.001
% decline of eGFR/year 7.5 ± 12.4 1.6 ± 4.7 15.8 ± 4.3*** 37.7 ± 11.2***,††† <0.001
Enter dialysis (%) 110 (14.3 %) 3 (0.5 %) 52 (38.0 %)*** 55 (76.4 %)***,††† <0.001
SBP_t (mmHg) <0.001 133.1 ± 13.9 130.5 ± 12.6 138.1 ± 14.2** 144.3 ± 14.9***,††† <0.001
Blood parameters
 Hb_t (g/dL) <0.001 12.6 ± 1.8 13.1 ± 1.6 11.5 ± 1.6*** 10.6 ± 1.4***,††† <0.001
 TP_t (g/dL) <0.001 7.0 ± 0.5 7.1 ± 0.4 6.9 ± 0.5*** 6.5 ± 0.6***,††† <0.001
 Alb_t (g/dL) <0.001 4.0 ± 0.4 4.1 ± 0.3 3.8 ± 0.4*** 3.5 ± 0.5***,††† <0.001
 BUN_t (mg/dL) <0.001 26.7 ± 13.9 21.3 ± 8.7 37.6 ± 13.3*** 48.5 ± 15.1***,††† <0.001
 Cr_t (mg/dL) <0.001 1.88 ± 1.21 1.38 ± 0.61 2.79 ± 1.19*** 4.08 ± 1.29***,††† <0.001
 UA_t (mg/dL) <0.001 6.7 ± 1.3 6.3 ± 1.2 7.6 ± 1.0 7.9 ± 1.1***,††† <0.001
 Na_t (mEq/L) 0.875 140.7 ± 2.2 140.9 ± 2.2 140.3 ± 1.9 139.8 ± 2.5***,† <0.001
 K_t (mEq/L) 0.009 4.51 ± 0.44 4.42 ± 0.40 4.74 ± 0.47 4.79 ± 0.48***,††† <0.001
 Cl_t (mEq/L) <0.001 105.7 ± 2.6 105.4 ± 2.4 106.2 ± 2.8 106.9 ± 3.3***,†† <0.001
 Na-Cl_t (mEq/L) <0.001 34.9 ± 3.4 35.3 ± 3.6 34.1 ± 2.4*** 32.9 ± 2.0***,††† <0.001
 cCa_t (mg/dL) <0.001 8.7 ± 0.4 8.7 ± 0.4 8.7 ± 0.4 8.6 ± 0.4 0.227
 P_t (mg/dL) <0.001 3.5 ± 0.5 3.4 ± 0.4 3.7 ± 0.5*** 4.2 ± 0.6***,††† <0.001
 CRP_t (mg/dL) <0.001 0.3 ± 0.4 0.2 ± 0.3 0.3 ± 0.4*** 0.4 ± 0.4** <0.001
 LDL-C_t (mg/dL) <0.001 104.6 ± 23.3 106.6 ± 22.7 99.8 ± 23.1 98.6 ± 26.0*,†† 0.001
Urine parameters (spot)
 TPU/CrU_t (g/g Cr) 0.192 1.06 ± 1.43 0.51 ± 0.74 2.10 ± 1.50*** 3.30 ± 1.94***,†† <0.001
 UB_score_t <0.001 0.40 ± 0.55 0.35 ± 0.56 0.48 ± 0.51 0.59 ± 0.51** <0.001
Antihypertensive drugs
 RASi_t (%) <0.001 626 (81.3 %) 449 (80.0 %) 114 (83.2 %) 63 (87.5 %) 0.254
 CCB_t (%) <0.001 491 (63.8 %) 326 (58.1 %) 107 (78.1 %)*** 58 (80.6 %)*** <0.001
 Diuretic_t (%) <0.001 314 (40.8 %) 172 (30.7 %) 90 (65.7 %)*** 52 (72.2 %)*** <0.001
 Other AHD_t (%) <0.001 184 (23.9 %) 107 (19.1 %) 50 (36.5 %)*** 27 (37.5 %)** <0.001

Groups 1, 2, and 3 correspond to % decline of eGFR per year <10 %, 10–25 %, and >25 %, respectively

t” following the parameter denotes the time-averaged value or follow-up value

eGFR estimated glomerular filtration rate, SBP systolic blood pressure, Hb hemoglobin, TP total protein, Alb albumin, BUN blood urea nitrogen, Cr creatinine, UA uric acid, Na sodium, K potassium, Cl chloride, cCa albumin-corrected calcium, P phosphorus, CRP C-reactive protein, LDL-C low-density lipoprotein cholesterol, TPU/CrU urine protein divided by urine creatinine, UB_score urine blood score, RASi RAS inhibitor, CCB calcium channel blocker, AHD antihypertensive drugs

§ p values vs. baseline values in the total patients by paired t test, Wilcoxon signed-rank test (CRP, TPU/CrU, and UB_score) or McNemar (RASi, CCB, Diuretic, and other AHD)

ANOVA, Kruskal–Wallis H test (CRP, TPU/CrU, and UB_score) or cross table analysis (Enter dialysis, RASi, CCB, Diuretic, and other AHD)

* p < 0.05, ** p < 0.01, *** p < 0.001 vs. Group 1; p < 0.05, †† p < 0.01, ††† p < 0.001 vs. Group 2 (ANOVA followed by Tukey post-test or cross table analysis)

*** p < 0.001 vs. Group 1; ††† p < 0.001 vs. Group 2 (Mann–Whitney U test)